Keros Therapeutics, Inc. (KROS)

Market Cap	2.17B
Revenue (ttm)	651,000
Net Income (ttm)	-181.57M
Shares Out	40.51M
EPS (ttm)	-5.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	413,217
Open	53.52
Previous Close	54.01
Day's Range	53.20 - 55.89
52-Week Range	27.31 - 73.00
Beta	1.24
Analysts	Strong Buy
Price Target	91.43 (+70.52%)
Earnings Date	Nov 6, 2024

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 8, 2020
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: KROS
• Website: https://www.kerostx.com

Analyst Forecast

According to 8 analysts, the average rating for KROS stock is "Strong Buy." The 12-month stock price forecast is $91.43, which is an increase of 70.52% from the latest price.

Price Target

$91.43

(70.52% upside)

Analyst Consensus: Strong Buy